" class="no-js "lang="en-US"> Diamyd Medical - Medtech Alert
Monday, September 25, 2023
Diamyd Medical | Pharmtech Focus

Diamyd Medical

About Diamyd Medical

Diamyd Medical

Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development.

Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively in-licensed GAD molecule. In-licensed technologies for GABA and Gliadin also have potential to become a key piece of the puzzle of a future solution to prevent, treat or cure autoimmune diabetes and other inflammation-related conditions.

Diamyd Medical’s share is traded on Nasdaq Stockholm First North, ticker DMYD B.

Related Story

Diamyd Medical brings Karin Rosén, M.D, PhD, to its Board of Directors

March 10 2023

Diamyd Medical today announced that Karin Rosén will join the Board of Directors as an […]

Diamyd Medical and Partners are Awarded SEK 40 Million in VINNOVA Funding for the Prevention of Autoimmune Diseases

September 24 2021

The Swedish governmental innovation agency VINNOVA provides SEK 40 million in financing for an innovation milieu in […]

Diamyd Medical Secures Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes

August 9 2021

The European Patent Office has informed Diamyd Medical that the Company’s patent application regarding prevention […]